Curis, Inc. (NASDAQ:CRIS) Sees Large Increase in Short Interest

Curis, Inc. (NASDAQ:CRIS) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 3,515,828 shares, a growth of 1,242.5% from the June 15th total of 261,877 shares. Based on an average daily volume of 17,237,537 shares, the short-interest ratio is currently 0.2 days. Approximately 191.5% of the company’s shares are short sold.

Analyst Ratings Changes

Several research firms have issued reports on CRIS. HC Wainwright reaffirmed a “buy” rating and set a $340.00 price objective on shares of Curis in a report on Friday, March 20th. Zacks Research downgraded Curis from a “hold” rating to a “strong sell” rating in a research report on Friday, May 22nd. Wall Street Zen upgraded Curis to a “hold” rating in a report on Saturday, March 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Curis has an average rating of “Reduce” and a consensus target price of $340.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC increased its position in shares of Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 10,586 shares in the last quarter. XTX Topco Ltd acquired a new position in Curis in the 4th quarter worth $26,000. Squarepoint Ops LLC increased its holdings in Curis by 17.9% during the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 8,973 shares in the last quarter. Focused Wealth Management Inc raised its stake in shares of Curis by 83.4% in the 1st quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 49,900 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Curis by 2,883,237.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 230,659 shares during the period. Institutional investors own 29.97% of the company’s stock.

Curis Stock Performance

Shares of CRIS stock remained flat at $4.96 during trading hours on Friday. The stock had a trading volume of 61,495 shares, compared to its average volume of 477,057. Curis has a one year low of $3.61 and a one year high of $40.28. The firm has a market capitalization of $9.67 million, a price-to-earnings ratio of -0.21 and a beta of 3.08. The firm’s fifty day simple moving average is $8.95 and its 200 day simple moving average is $14.38.

Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($25.00) EPS for the quarter, missing analysts’ consensus estimates of ($6.53) by ($18.47). On average, equities analysts predict that Curis will post -25.5 earnings per share for the current fiscal year.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.